NASDAQ:GANX

Gain Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy GANX

*Your capital is at risk

$1.80

-0.0200 (-1.10%)

At Close: Jul 10, 2026

Currently predicting for Tue, 14 Jul 2026

GANX Live board

Community Bull/Bear

Target Next close

Join the GANX prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

GANX Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For GANX

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

GANX Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT GAIN THERAPEUTICS, INC.

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing s...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	11.34%	Jun 29
NMRK $15.02	1.20%	Jun 24
NESR $25.07	14.16%	Jun 23
CAG $13.43	2.98%	Jun 23
GIB $66.69	0.555%	Jun 12

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by